Inactive Instrument

AbbVie Stock Euronext Paris

Equities

ABBV

US00287Y1091

Pharmaceuticals

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 55.14B 50.65B Sales 2025 * 58.11B 53.38B Capitalization 289B 266B
Net income 2024 * 7.74B 7.11B Net income 2025 * 10.64B 9.78B EV / Sales 2024 * 6.22 x
Net Debt 2024 * 53.62B 49.25B Net Debt 2025 * 47.29B 43.44B EV / Sales 2025 * 5.79 x
P/E ratio 2024 *
31.8 x
P/E ratio 2025 *
24.4 x
Employees -
Yield 2024 *
3.78%
Yield 2025 *
3.97%
Free-Float 96.37%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 70 12-12-31
Director of Finance/CFO 57 12-12-31
President 53 11-12-31
Members of the board TitleAgeSince
Director/Board Member 63 12-12-31
Director/Board Member 66 12-12-31
Director/Board Member 70 12-12-31
More insiders
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Related indices
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW